Fig. 2From: Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutationComparison of chromosomic aberrations in primary tumor (PR) and in its Patient derived xenograft (PDX). In red, the loss regions, in blue the gain regionsBack to article page